Business Context and Reporting Period
Company: Amgen Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2005
Business Overview: Amgen is a global biotechnology company operating in a single segment: human therapeutics. The company discovers, develops, manufactures, and markets products in inflammation, nephrology, and supportive cancer care. Principal products include Aranesp, EPOGEN, Neulasta, NEUPOGEN, and Enbrel (co-promoted with Wyeth in the U.S. and Canada).
Key Financial Metrics (Year Ended Dec 31, 2005)
| Metric | 2005 | 2004 | Change |
|---|---|---|---|
| Total Revenues | $12,430 million | $10,550 million | +17.8% |
| Product Sales | $12,022 million | $9,977 million | +20.5% |
| Net Income | $3,674 million | $2,363 million | +55.5% |
| Diluted EPS | $2.93 | $1.81 | +61.9% |
| Operating Income | $4,848 million | $3,348 million | +44.8% |
| Operating Margin | 39.0% | 31.7% | +7.3 pts |
| Operating Cash Flow | $4,911 million | $3,697 million | +32.8% |
| Long-Term Debt | $3,957 million | $3,937 million | +0.5% |
| Cash & Equivalents | $1,840 million | $1,526 million | +20.6% |
| Total Assets | $29,297 million | $29,221 million | +0.3% |
Material Changes vs. Prior Period
- Revenue Growth: Driven primarily by strong sales growth in Aranesp (+32%), Enbrel (+35%), and Neulasta (+32%). EPOGEN sales declined 6% due to conversion to Aranesp in hospital dialysis clinics and lower demand.
- Profitability: Net income increased significantly, aided by the absence of the $554 million in-process research and development (IPR&D) write-off recorded in 2004 related to the Tularik acquisition.
- Expense Trends: R&D expenses rose 14% to $2,314 million due to increased clinical trial costs (specifically for denosumab) and staff integration. SG&A expenses increased 9% to $2,790 million, largely due to higher marketing expenses and Wyeth profit sharing on Enbrel.
- Debt Structure: In March 2005, the company repurchased approximately 40% of its outstanding convertible notes ($1.2 billion cash) when holders exercised a put option. The remaining notes were reclassified as non-current liabilities.
Guidance, Outlook, and Risks
Management Commentary & Outlook
- R&D Investment: Management expects R&D expenses to increase by 30-40% in 2006, driven by large-scale Phase 3 trials for denosumab (osteoporosis) and other late-stage candidates.
- Sales Growth: While Aranesp, Enbrel, and Neulasta are expected to drive growth, the company anticipates lower year-over-year sales growth rates compared to previous years due to the large base of existing sales and increased competition.
- Reimbursement: The company believes the Medicare Modernization Act (MMA) changes effective in 2006 will not have a significant negative impact on 2006 business, though reimbursement rates for EPOGEN are expected to decrease.
- Acquisition: Amgen signed a definitive agreement in December 2005 to acquire Abgenix, Inc. for approximately $2.2 billion in cash plus assumption of debt, expected to close by April 2006.
Risks and Contingencies
- Biosimilar Competition: Principal European patents for erythropoietin and G-CSF have expired or are expiring (August 2006). The company expects biosimilar products to enter the EU market in late 2006 and mid-2007, respectively, potentially impacting sales of Aranesp, Neulasta, and NEUPOGEN.
- Manufacturing Concentration: Substantially all formulation, fill, and finish activities for principal products occur in Puerto Rico. Disruptions (e.g., natural disasters) could severely impact supply.
- Legal Proceedings: The company faces ongoing litigation regarding Average Wholesale Price (AWP) reporting, patent disputes (e.g., Roche, Transkaryotic Therapies), and government investigations into pricing practices.
Investor Verification Checklist
- Reimbursement Impact: Verify the actual impact of the 2006 Medicare Physician Fee Schedule and ASP+6% reimbursement methodology on EPOGEN and Aranesp sales volumes.
- Biosimilar Timeline: Monitor the approval and market entry of biosimilar erythropoietin and G-CSF products in the European Union.
- Abgenix Integration: Track the closing of the Abgenix acquisition and the subsequent integration of panitumumab into the commercial pipeline.
- Denosumab Trials: Review results from the large-scale Phase 3 trials for denosumab in osteoporosis and bone metastases, which are driving the projected 30-40% R&D expense increase.
- Legal Resolutions: Monitor outcomes of the AWP litigation and patent disputes with Roche and Transkaryotic Therapies for potential financial liabilities.